Next Generation Sequencing and Molecular Biomarkers in Ovarian Cancer-An Opportunity for Targeted Therapy

Overview

Journal Diagnostics (Basel)

Specialty Radiology

Date 2022 Apr 23

PMID 35453890

Authors

Laura M Harbin

Holly H Gallion

Derek B Allison

Jill M Kolesar

Affiliations

Soon will be listed here.

Abstract

Ovarian cancer is the deadliest of all gynecologic malignancies claiming the lives of nearly 14,000 women in the United States annually. Despite therapeutic advances, the ovarian cancer mortality rate has remained stagnant since the 1980's. The molecular heterogeneity of ovarian cancers suggest they may be more effectively treated via precision medicine. Current guidelines recommend germline and somatic testing for all new epithelial ovarian cancer diagnoses to assist providers in identifying candidates for targeted therapies. Next generation sequencing (NGS) identifies targetable, driver, and novel mutations used to guide treatment decisions. Performing NGS is standard of care in many other malignancies, but for ovarian cancer the use of NGS in daily practice is still emerging. This review discusses the targetable genetic mutations and role of NGS and molecular biomarker testing in the treatment of ovarian cancer.

Citing Articles

Utilization of miRNAs as Biomarkers for the Diagnosis, Prognosis, and Metastasis in Gynecological Malignancies.

Lazaridis A, Katifelis H, Kalampokas E, Lambropoulou D, Aravantinos G, Gazouli M Int J Mol Sci. 2024; 25(21).

PMID: 39519256 PMC: 11546551. DOI: 10.3390/ijms252111703.

Identification of potentially actionable genetic variants in epithelial ovarian cancer: a retrospective cohort study.

Fieuws C, Van der Meulen J, Proesmans K, De Jaeghere E, Loontiens S, Van Dorpe J NPJ Precis Oncol. 2024; 8(1):71.

PMID: 38519644 PMC: 10959961. DOI: 10.1038/s41698-024-00565-2.

Next-generation sequencing-based analysis of homologous recombination repair gene variant in ovarian cancer.

Song Y, Ran W, Jia H, Yao Q, Li G, Chen Y Heliyon. 2024; 10(2):e23684.

PMID: 38298632 PMC: 10827683. DOI: 10.1016/j.heliyon.2023.e23684.

A Benchmark of In-House Homologous Recombination Repair Deficiency Testing Solutions for High-Grade Serous Ovarian Cancer Diagnosis.

Guarischi-Sousa R, Kroll J, Bonaldi A, Pierry P, Villela D, Souza C Diagnostics (Basel). 2023; 13(21).

PMID: 37958189 PMC: 10648202. DOI: 10.3390/diagnostics13213293.

Diagnostics and treatment of ovarian cancer in the era of precision medicine - opportunities and challenges.

Buklaho P, Kisluk J, Niklinski J Front Oncol. 2023; 13:1227657.

PMID: 37746296 PMC: 10516548. DOI: 10.3389/fonc.2023.1227657.

References

Willis J, Lefterova M, Artyomenko A, Kasi P, Nakamura Y, Mody K . Validation of Microsatellite Instability Detection Using a Comprehensive Plasma-Based Genotyping Panel. Clin Cancer Res. 2019; 25(23):7035-7045. DOI: 10.1158/1078-0432.CCR-19-1324. View

Marabelle A, Fakih M, Lopez J, Shah M, Shapira-Frommer R, Nakagawa K . Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet Oncol. 2020; 21(10):1353-1365. DOI: 10.1016/S1470-2045(20)30445-9. View

Huang B, Chen Q, Allison D, El Khouli R, Peh K, Mobley J . Molecular Tumor Board Review and Improved Overall Survival in Non-Small-Cell Lung Cancer. JCO Precis Oncol. 2021; 5. PMC: 8492377. DOI: 10.1200/PO.21.00210. View

Mirza M, Monk B, Herrstedt J, Oza A, Mahner S, Redondo A . Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer. N Engl J Med. 2016; 375(22):2154-2164. DOI: 10.1056/NEJMoa1611310. View

Gershenson D, Miller A, Brady W, Paul J, Carty K, Rodgers W . Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281/LOGS): an international, randomised, open-label, multicentre, phase 2/3 trial. Lancet. 2022; 399(10324):541-553. PMC: 8819271. DOI: 10.1016/S0140-6736(21)02175-9. View

Malapelle U, Parente P, Pepe F, De Luca C, Pisapia P, Sgariglia R . Evaluation of Micro Satellite Instability and Mismatch Repair Status in Different Solid Tumors: A Multicenter Analysis in a Real World Setting. Cells. 2021; 10(8). PMC: 8391221. DOI: 10.3390/cells10081878. View

Lemery S, Keegan P, Pazdur R . First FDA Approval Agnostic of Cancer Site - When a Biomarker Defines the Indication. N Engl J Med. 2017; 377(15):1409-1412. DOI: 10.1056/NEJMp1709968. View

Cocco E, Scaltriti M, Drilon A . NTRK fusion-positive cancers and TRK inhibitor therapy. Nat Rev Clin Oncol. 2018; 15(12):731-747. PMC: 6419506. DOI: 10.1038/s41571-018-0113-0. View

Aysal A, Karnezis A, Medhi I, Grenert J, Zaloudek C, Rabban J . Ovarian endometrioid adenocarcinoma: incidence and clinical significance of the morphologic and immunohistochemical markers of mismatch repair protein defects and tumor microsatellite instability. Am J Surg Pathol. 2011; 36(2):163-72. DOI: 10.1097/PAS.0b013e31823bc434. View

10.

Radu M, Pradatu A, Duica F, Micu R, Cretoiu S, Suciu N . Ovarian Cancer: Biomarkers and Targeted Therapy. Biomedicines. 2021; 9(6). PMC: 8235073. DOI: 10.3390/biomedicines9060693. View

11.

Bi F, Chen Y, Yang Q . Significance of tumor mutation burden combined with immune infiltrates in the progression and prognosis of ovarian cancer. Cancer Cell Int. 2020; 20:373. PMC: 7405355. DOI: 10.1186/s12935-020-01472-9. View

12.

Drilon A, Siena S, Ou S, Patel M, Ahn M, Lee J . Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1). Cancer Discov. 2017; 7(4):400-409. PMC: 5380583. DOI: 10.1158/2159-8290.CD-16-1237. View

13.

Matulonis U, Shapira-Frommer R, Santin A, Lisyanskaya A, Pignata S, Vergote I . Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study. Ann Oncol. 2019; 30(7):1080-1087. DOI: 10.1093/annonc/mdz135. View

14.

Coleman R, Oza A, Lorusso D, Aghajanian C, Oaknin A, Dean A . Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017; 390(10106):1949-1961. PMC: 5901715. DOI: 10.1016/S0140-6736(17)32440-6. View

15.

Stover E, Fuh K, Konstantinopoulos P, Matulonis U, Liu J . Clinical assays for assessment of homologous recombination DNA repair deficiency. Gynecol Oncol. 2020; 159(3):887-898. DOI: 10.1016/j.ygyno.2020.09.029. View

16.

Contos G, Baca Y, Xiu J, Brown J, Holloway R, Korn W . Assessment of immune biomarkers and establishing a triple negative phenotype in gynecologic cancers. Gynecol Oncol. 2021; 163(2):312-319. DOI: 10.1016/j.ygyno.2021.09.011. View

17.

Murphy M, Wentzensen N . Frequency of mismatch repair deficiency in ovarian cancer: a systematic review This article is a US Government work and, as such, is in the public domain of the United States of America. Int J Cancer. 2010; 129(8):1914-22. PMC: 3107885. DOI: 10.1002/ijc.25835. View

18.

Cheasley D, Nigam A, Zethoven M, Hunter S, Etemadmoghadam D, Semple T . Genomic analysis of low-grade serous ovarian carcinoma to identify key drivers and therapeutic vulnerabilities. J Pathol. 2020; 253(1):41-54. DOI: 10.1002/path.5545. View

19.

Bansal A, Srinivasan R, Rohilla M, Rai B, Rajwanshi A, Suri V . Immunotyping in tubo-ovarian high-grade serous carcinoma by PD-L1 and CD8+ T-lymphocytes predicts disease-free survival. APMIS. 2021; 129(5):254-264. DOI: 10.1111/apm.13116. View

20.

Laetsch T, Hong D . Tropomyosin Receptor Kinase Inhibitors for the Treatment of TRK Fusion Cancer. Clin Cancer Res. 2021; 27(18):4974-4982. DOI: 10.1158/1078-0432.CCR-21-0465. View